| abstract |
FIELD: pharmaceutical chemistry. n SUBSTANCE: invention provides novel compounds of general formula (I) and pharmaceutically acceptable salts thereof, wherein G represents glycin; D aspartic acid; R 1 group -(CH 2 )n- or -(CH 2 )n-C 6 H 4 -; n is integer from 1 to 10; h is 1 or 2; X 1 represents amino acid residue having one functional deviation such as amine; X 2 and X 4 independently represent amino acid residue capable of forming disulfide bond; X 3 represents hydrophobic amino acid such as phenylalanine; X 6 represents group -NH-[CH-]-C(O)-; X 7 is missing or represents biomodifying grouping consisting of monodisperse poly(ethylene glycol): (II), wherein is integer from 1 to 10; C-end unit represents amide group or 1-10 amino acid residues; Z 1 chelating group or reporter group; and W 1 is missing or represents spacing moiety derived from glutaric or succinic acid. Compounds of invention are designed as diagnostic agents for visualization or as therapeutic agents, the two agent types being directional vectors capable of binding to integrin receptors. n EFFECT: expanded diagnostic and therapeutic possibilities. n 19 cl, 3 tbl, 5 ex |